# Bioparin **Type:** venture **Status:** Draft **Confidence:** Medium **Focus:** synthetic heparin, biomanufacturing, anticoagulants, supply chain resilience, university spinout **Stage:** Early (STTR-funded) **Location:** Salt Lake City, UT **Updated:** 2026-06-19 **Needs-reviewed:** 2026-06-19 **Hero:** https://picsum.photos/seed/bioparin-2026/1600/1100 **Relates:** cites [Official Website: Bioparin](bioparin-official-website.md) ## Summary Bioparin is an early-stage University of Utah spinout, founded around 2023, working to produce heparin synthetically using cell-based or enzymatic biosynthesis rather than animal extraction. Heparin is the most widely used anticoagulant in medicine — deployed in dialysis, cardiac surgery, ICU care, and treatment of blood clots — and the global supply chain is heavily dependent on pig intestines sourced predominantly from China. Bioparin has received STTR federal funding. No major venture capital round has been publicly identified. ## Impact Heparin's supply chain is one of the most fragile in all of medicine. Approximately 80 percent of the world's supply comes from the small intestines of Chinese-raised pigs. The 2008 heparin contamination crisis — linked to adulterated Chinese heparin — killed at least 81 people in the United States and caused thousands of adverse reactions. African swine fever outbreaks have since threatened supply further. A synthetic alternative would eliminate pig dependence, enable precise control of the heparin fragment mixture (not achievable with animal-sourced product), remove contamination risk, and allow supply to scale with demand rather than with swine herd size. The population of patients who receive heparin or heparin derivatives is measured in tens of millions annually. If Bioparin reaches commercial production, the public health impact footprint is large — not because the product is exotic, but because it addresses a known, recurring, life-threatening supply vulnerability. ## What They Are Building Bioparin is attempting synthetic heparin production through one of two routes: cell-based biosynthesis, in which engineered cells express the full enzyme cascade needed to produce correctly sulfated heparin, or cell-free enzymatic synthesis, in which purified enzymes run the reactions outside cells in a more controlled but potentially more expensive process. Heparin is not a single molecule — it is a polysaccharide mixture whose anticoagulant activity depends on a specific sulfation pattern. Producing it synthetically requires not just generating the carbohydrate backbone but also achieving the correct sulfation at sufficient yield, then demonstrating equivalence to USP heparin for FDA purposes. This is a high-difficulty technical target. Academic groups have pursued synthetic heparin for over two decades without a commercial product reaching the market. Bioparin's early-stage STTR funding suggests the federal government views the problem as tractable and worth pursuing. ## What They Need Now Bioparin is at lab scale. The company likely needs synthetic biologists with carbohydrate metabolism expertise, process engineers with biosynthesis scale-up experience, carbohydrate chemists, and regulatory affairs specialists familiar with drug biosimilar pathways. At this stage, non-dilutive federal funding (further SBIR/STTR awards, NIH grants) is the most plausible near-term capital path, with seed investment from life sciences investors as a parallel pursuit. ## Who Could Help Relevant helpers include NIH and BARDA program officers interested in supply chain resilience for essential medicines, bioprocess engineering collaborators, the University of Utah Technology Licensing Office, carbohydrate chemistry experts, and early-stage life sciences investors who can tolerate a long development timeline. FDA regulatory advisors familiar with the heparin biosimilar pathway would be valuable early. ## Utah Context The University of Utah spinout infrastructure — including the Technology Licensing Office and federal grant support through the Utah Science Technology and Research (USTAR) initiative — provides a credible early path for a company at Bioparin's stage. Salt Lake City's life sciences ecosystem is growing, though it skews toward medical devices and digital health rather than small-molecule or biologic drug development. Bioparin is an unusual bet in that context: a biopharma play on an essential generic rather than a novel therapeutic. ## Evidence - [Official Website: Bioparin](bioparin-official-website.md) ## See Also ## Open Questions - Which biosynthetic route is Bioparin pursuing — cell-based or cell-free enzymatic synthesis? - Who are the founders and principal investigators, and what is their prior heparin chemistry experience? - Has the company established a clear FDA regulatory strategy for heparin equivalence? - What is the current status of STTR funding — which phase, and from which agency? - What does Bioparin's website URL currently show, given that the legacy source listed "search: Bioparin University of Utah" rather than a direct URL? - Competing academic groups (notably Robert Linhardt at RPI and others) have also pursued synthetic heparin — how does Bioparin's approach compare? - Price parity with Chinese pig-intestine extraction is a very hard economic bar — what production cost targets has the company identified? - The placeholder hero should be replaced with a cleared laboratory or process photograph when rights are confirmed.